FRM
IMMU

Fox Run Management’s Immunomedics Inc IMMU Stock Holding History

Fox Run Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-12,898
Closed -$171K – 594
2019
Q3 		$171K Buy
+12,898
New +$190K 0.16% 315
2018
Q2 		– Sell
-10,341
Closed -$151K – 1005
2018
Q1 		$151K Buy
+10,341
New +$169K 0.04% 660

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Fox Run Management's IMMU Position: Q4 2019 in Review

Fox Run Management sold out of Immunomedics Inc (IMMU) in Q4 2019, closing a stake of 12,898 shares — an estimated $171K sold.

Fox Run Management first reported a position in IMMU in Q1 2018 and held it in 2 quarters. The position peaked at $171K in Q3 2019. 245 funds tracked by Wall St. Rank hold IMMU as of Q4 2019.

  • Fox Run Management reported no remaining Immunomedics Inc position as of Q4 2019 after selling out during the quarter.
  • Fox Run Management sold 12,898 Immunomedics Inc shares in Q4 2019, an estimated $171K.
  • Fox Run Management first reported a position in Immunomedics Inc in Q1 2018 and held it in 2 quarters.
  • Fox Run Management's Immunomedics Inc position peaked at $171K in Q3 2019.
  • 245 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2019.

Based on Fox Run Management's 13F filing for Q4 2019, filed 14 Feb 2020.